Share

July 2017; 4 (4) ArticleOpen Access

Both cladribine and alemtuzumab may effect MS via B-cell depletion

David Baker, Samuel S. Herrod, Cesar Alvarez-Gonzalez, Lukasz Zalewski, Christo Albor, Klaus Schmierer
First published June 5, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000360
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2954

Share

This article has a correction. Please see:

Article Information

vol. 4 no. 4 e360
DOI: 
https://doi.org/10.1212/NXI.0000000000000360
PubMed: 
28626781
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received January 16, 2017
  • Accepted in final form April 5, 2017
  • First Published June 5, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. David Baker, PhD,
    2. Samuel S. Herrod, BSc,
    3. Cesar Alvarez-Gonzalez, PhD,
    4. Lukasz Zalewski, PhD,
    5. Christo Albor, PhD and
    6. Klaus Schmierer, PhD
  1. David Baker, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Patent filed via the university concerning the treatment of multiple sclerosis with cladribine and other compounds

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant for a Commercial entity (Canbex Therapeutics) that is unrelated to the subject of the manuscript

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. My laboratory received funds for research from a commercial entity (Genzyme Sanofi), unrelated to the subject of the manuscript in the past two years

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. The laboratory received funds for research from a academic entities unrelated to the subject of the manuscript

    Research Support, Foundations and Societies:

    1. The laboratory received funds for research from Charities (Multiple sclerosis Society, Innovative UK/Technology Strategy Board, Diabetes UK, National Multiple Sclerosis Society), Fight for Sight for studies unrelated to the subject of the manuscript

    Stock/Stock Options/Board of Directors Compensation:

    1. I have recieved stock options from a commercial entity (Canbex Therapeutics) in the past to years or studies unrelated to the subject of the manuscript.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. I provided consultancy to legal company acting on behalf of Teva, which was unrelated to the subject of the manuscript.

  2. Samuel S. Herrod, BSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. The laboratory received funds for research from academic entities unrelated to the subject of the manuscript

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Cesar Alvarez-Gonzalez, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. The laboratory received funds for research from academic entities unrelated to the subject of the manuscript.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Lukasz Zalewski, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Christo Albor, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. The laboratory received funds for research from academic entities unrelated to the subject of the manuscript.

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Klaus Schmierer, PhD
    7. Scientific Advisory Boards:

    1. (i) Novartis (ii) Biogen (iii) Merck Inc (iv) Teva (v) Merck Serono (vi) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (i) Novartis, speaker honoraria (ii) Biogen, speaker honoraria (iii) Merck Inc, speaker honoraria (iv) Teva, speaker honoraria (v) Merck Serono, speaker honoraria (vi) Cinnagen, speaker honoraria (vii) Roche, speaker honoraria

    Editorial Boards:

    1. MS Reports, editorial board, since Jun 2014

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Barts Charity (468/1506) National MS Society (RG 4421A1/1; RG 4618A2/1) Royal College of Radiologists

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the BartsMS (D.B., S.S.H., C.A.G., C.A., K.S.), Blizard Institute, ITS Research (L.Z.), Queen Mary University of London; and Barts Health NHS Trust (K.S.), Emergency Care & Acute Medicine Neuroscience Clinical Academic Group, London, UK.
  1. Correspondence to Dr. Schmierer: k.schmierer{at}qmul.ac.uk
View Full Text

Article usage

Article usage: June 2017 to February 2023

AbstractFullPdfSource
Jun 2017591605172Highwire
Jun 2017384856pmc
Jul 20172777999Highwire
Jul 2017113126159pmc
Aug 201710940474Highwire
Aug 20178698129pmc
Sep 2017899651Highwire
Sep 20176995112pmc
Oct 2017689746Highwire
Oct 2017606590pmc
Nov 20175013852Highwire
Nov 20178485103pmc
Dec 201726920Highwire
Jan 201827926Highwire
Feb 201838824Highwire
Mar 20182014845Highwire
Apr 2018168016Highwire
Apr 2018446182pmc
May 201887514Highwire
Jun 201858523Highwire
Jun 2018356684pmc
Jul 2018115025Highwire
Aug 201886215Highwire
Aug 201893639pmc
Sep 2018710630Highwire
Oct 2018518623Highwire
Nov 2018615231Highwire
Dec 2018622015Highwire
Jan 2019418924Highwire
Feb 20192219036Highwire
Mar 201959832Highwire
Apr 201972716Highwire
May 2019143016Highwire
Jun 201944221Highwire
Jul 201993832Highwire
Aug 201975453Highwire
Sep 201983737Highwire
Oct 201974240Highwire
Nov 201945026Highwire
Dec 2019134719Highwire
Jan 2020164023Highwire
Feb 202045123Highwire
Mar 202076426Highwire
Apr 202097129Highwire
May 2020119633Highwire
Jun 2020137339Highwire
Jul 202094418Highwire
Aug 2020124121Highwire
Sep 2020115522Highwire
Oct 202075521Highwire
Nov 202045037Highwire
Dec 202015339Highwire
Jan 202163716Highwire
Feb 2021114419Highwire
Mar 202163221Highwire
Apr 202193534Highwire
May 2021174214Highwire
Jun 2021215226Highwire
Jul 2021103923Highwire
Aug 202175622Highwire
Sep 202175815Highwire
Oct 2021168340Highwire
Nov 2021810441Highwire
Dec 202177123Highwire
Jan 202258133Highwire
Feb 2022187044Highwire
Mar 202217216Highwire
Apr 20221046725Highwire
May 2022329119Highwire
Jun 202255030Highwire
Jul 202266120Highwire
Aug 202287916Highwire
Sep 20221010833Highwire
Oct 2022910126Highwire
Nov 20222112937Highwire
Dec 202255223Highwire
Jan 2023810917Highwire
Feb 202324513Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles